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Abstract
Introduction: Acute haemodynamic complications are common after cardiac surgery and optimal perioperative
use of inotropic agents, typically guided by haemodynamic variables, remains controversial. The aim of this study
was to examine the relationship of inotrope use to hospital mortality and renal dysfunction.
Material and methods: A retrospective cohort study of 1,326 cardiac surgery patients was carried out at two
university-affiliated ICUs. Multivariable logistic regression analysis and propensity matching were performed to
evaluate whether inotrope exposure was independently associated with mortality and renal dysfunction.
Results: Patients exposed to inotropes had a higher mortality rate than those not exposed. After adjusting for
differences in Parsonnet score, left ventricular ejection fraction, perioperative intraaortic balloon pump use, bypass
time, reoperation and cardiac index, inotrope exposure appeared to be independently associated with increased
hospital mortality (adjusted odds ratio (OR) 2.3, 95% confidence interval (95% CI) 1.2 to 4.5) and renal dysfunction
(adjusted OR 2.7, 95% CI 1.5 to 4.6). A propensity score-matched analysis similarly demonstrated that death and
renal dysfunction were significantly more likely to occur in patients exposed to inotropes (P = 0.01).
Conclusions: Postoperative inotrope exposure was independently associated with worse outcomes in this cohort
study. Further research is needed to better elucidate the appropriate use of inotropes in cardiac surgery.
Introduction
Low cardiac output syndrome is a common complica-
tion in patients undergoing cardiac surgery [1]. The
aetiology is multifactorial and is believed to be related
to a combination of myocardial ischaemia, reperfusion
injury, cardioplegia-induced myocardial dysfunction and
preexisting cardiac disease [2]. The administration of
fluids and inotropes and the use of ventricular assist
devices are common therapies in the management of
low cardiac output syndrome. Physiological variables
such as cardiac index, mixed venous oxygen saturation,
oxygen delivery and lactate levels, obtained either from
a cardiac output monitoring device or by measuring
oxygen consumption and delivery, are often used to
guide therapy. Inotropic agents are frequently used and
titrated to achieve certain target levels of these physiolo-
gical variables [3].
However, there is no consensus regarding low cardiac
output syndrome in terms of both the physiological para-
meters that define it and the interventions used to treat it
[2]. The use of inotropes has been described to be both
centre- and physician-dependent and as being adminis-
tered to as few as 5% or to as many as 100% of patients
undergoing elective coronary bypass surgery [4-6].
Although inotropes have been demonstrated to improve
haemodynamics and measured physiological variables
[2], they may be a source of increased mortality and mor-
bidity as they can increase cardiac arrhythmias and
ischaemia [7]. Very few randomised, controlled trials
comparing the different agents used and their effects on
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undergo cardiac surgery [2]. In a recent observational
study, the receipt of dobutamine perioperatively was
associated with increased mortality [8]. In addition,
investigators in randomised, controlled trials of inotropes
in patients with heart failure and left ventricular dysfunc-
tion have reported increased side effects and increased
mortality [9].
While the use of inotropes as part of a protocol to tar-
get physiological parameters within the first six hours
after cardiac surgery has been shown to improve out-
comes in patients with sepsis [10], it is unclear whether
their use in the postoperative cardiac care setting is
favourable with respect to morbidity and mortality. This
study was undertaken to evaluate the relationship of
inotrope use to morbidity and mortality in a cohort of
consecutive patients undergoing cardiac surgery.
Materials and methods
Setting and study population
This study was conducted at two adult tertiary care uni-
versity-affiliated hospitals. Data were collected retrospec-
tively between 1 January 2005 and 31 December 2005 by
trained reviewers using standardised data collection sheets.
Consecutive patients who had undergone coronary artery
bypass graft (CABG) surgery, valve replacement or repair
or combined CABG and valvular or aortic procedures
were included in the study. Patients who had undergone a
heart transplant, pulmonary thromboendarterectomy or
placement of a ventricular assistance device were
excluded.
All patients had been admitted postoperatively to the
ICU. A Swan-Ganz catheter had been used perioperatively
at both hospitals to guide patient resuscitation. Serum lac-
tate and mixed venous oxygen saturation levels had been
measured in all patients at one site, and selected patients
at the other site. To avoid bias, only the data from the
patients treated at the hospital with routinely measured
serum lactate and mixed venous oxygen saturation were
used for the analysis of those variables.
All research was conducted in keeping with the princi-
ples outlined in the Declaration of Helsinki. The research
ethics committee of the McGill University Health Centre
Research Institute approved the study. The hospital’s
ethics committee waived the need for informed consent as
the data were collected retrospectively.
Exposure, covariates and end points
The primary drug exposure studied was postoperative
inotrope use. Epinephrine, milrinone and dobutamine
were the main inotropes used in the study centres. The
definition of ‘postoperative inotrope use’ varied for each
medication. Milrinone exposure was defined as adminis-
tration of any dose for any length of time in the ICU.
Dobutamine exposure was defined as delivery of any
dose as long as it was administered for at least three
hours in the ICU. Epinephrine exposure was defined as a
minimum duration of three hours in the ICU if the dose
was < 5 μg/minute or any duration if doses ≥ 5 μg/min-
ute were used. Consistent with the definitions used by
other authors [2], norepinephrine and vasopressin were
not considered inotropes.
The primary study outcomes were hospital mortality
and the occurrence of postoperative renal dysfunction.
Renal dysfunction was defined by an increase in creati-
nine ≥ 200% from baseline in the first five postoperative
days or new renal replacement therapy at any point dur-
ing hospitalisation. These definitions are consistent with
stages 2 and 3 of the Acute Kidney Injury Network clas-
sification system [11]. Secondary outcomes were ICU
length of stay and hospital length of stay.
Data were collected regarding patient age, sex, Parsonnet
score, medical history, procedure-related variables and
six-hour postoperative physiological variables. Medical his-
tories were abstracted from patient records. Conditions
considered were any prior cardiac surgery, hypertension,
diabetes, atrial fibrillation, preoperative hospitalisation for
heart failure, preoperative renal dysfunction, preoperative
dialysis, preoperative left ventricular ejection fraction and
left ventricular dysfunction. Preoperative renal dysfunction
was defined by a preoperative creatinine level ≥ 150 μmol/
L. Left ventricular dysfunction was defined as left ventricu-
lar ejection fraction < 30%. Procedure-related variables
consisted of cardiac procedures, perioperative intraaortic
balloon pump use, reoperation, emergency operation,
mean bypass time and severe postoperative bleeding. Car-
diac procedures were separated into a CABG-only group
and a group who had undergone other procedures, defined
as (1) valve repair or replacement or (2) combined CABG
and valve repair or replacement. An emergency operation
was defined as a cardiac procedure occurring within 24
hours of acute coronary syndrome or immediately after a
percutaneous intervention. Reoperation was defined as the
need for reoperation 48 hours after the initial cardiac pro-
cedure. Severe postoperative bleeding was defined as
blood loss > 2.5 L within 24 hours after the initial cardiac
procedure. The six-hour postoperative physiological vari-
ables consisted of mean arterial pressure, cardiac index,
mixed venous oxygen saturation and serum lactate. These
tests were performed in the ICU six hours after the
operation.
Data analysis
Preoperative variables, intraoperative variables and out-
comes in patients exposed or unexposed to inotropes
were compared using Student’s t-test and the Wilcoxon
rank-sum test for continuous variables and a c
2 test for
categorical variables. Multivariable logistic regression
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exposure and outcomes after adjusting for possible con-
founding variables. A forward stepwise procedure was
first used to assess inotrope exposure in the model.
Variables were kept in the model if they were believed
to be clinically important or if they altered the associa-
tion between inotrope exposure and outcome by ≥ 10%.
Covariates included in the model were Parsonnet score,
left ventricular dysfunction, perioperative intraaortic bal-
loon pump use, bypass time, reoperation, postoperative
bleeding, preoperative renal dysfunction, treatment hos-
pital, aprotinin use and cardiac index < 2.2 [3]. Variables
included in the Parsonnet score were not included in
the model, other than a low left ventricular ejection
fraction, as we thought this might strongly influence
decision making with respect to inotrope use, and its
weighting in the Parsonnet score might not reflect this.
Colinearity between left ventricular ejection fraction and
Parsonnet score was excluded as the variance inflation
factor was < 2.5.
A second analytic method, propensity score matching,
was performed to evaluate the association between ino-
trope exposure and outcomes. A one-to-many greedy
five-to-one digit technique was performed to match one
control in the no agent group (control group) by one
case (inotrope-exposed). A ‘greedy five-to-one digit
match’ means that the cases were first matched to con-
trols on five digits of the propensity score. For those that
did not match, cases were then matched to controls on
four digits of the propensity score. This continued down
to a one-digit match on propensity scores for those that
remained unmatched. If a one-digit match was not possi-
ble, the case remained unmatched and was not included
in the matched case control analysis. Matching variables
included Parsonnet score, low left ventricular ejection
fraction, age, sex, bypass time, procedure type, CABG
only or other procedures, and perioperative intraaortic
balloon pump use. In this matched sample, baseline char-
acteristics and outcomes were compared between ino-
trope exposed and unexposed groups by performing
paired t-tests for continuous variables and McNemar’s
test for categorical values.
Because of previous literature correlating patient out-
comes with physiological goals [10] and recommendations
that certain levels of physiologic variables be targeted [3],
we examined the relationship between measured six-hour
physiologic variables and outcomes. Specifically, oxygen
delivery, cardiac index, serum lactate and mixed venous
oxygen saturation were examined. The six-hour post-
operative physiological variables were categorised with
cutoffs based on recommendations in the literature [3,10],
with the exception of oxygen delivery, which was based on
the median value derived from the data. We examined the
relationship between inotrope exposure and outcomes
after stratifying by the six-hour physiological variables. All
data processing and analyses were performed using SAS
version 9.2 software (SAS Institute, Cary, NC, USA).
Results
In total, 1,326 patients were initially included in the
study. Their mean age was 66 years, with 10% of the
cohort being older than 80 years of age and more than
two-thirds being male. The majority of the procedures
were CABG operations, and the mean Parsonnet score
(± SD) was 13.4 ± 10.6 (Table 1). Over 97% of the
patients had Swan-Ganz catheters inserted. Fifty percent
of patients were exposed to inotropes intraoperatively,
and forty-two percent were exposed postoperatively. The
hospital mortality rate was 7.8%, and renal dysfunction
occurred in 8.3% of the patients (Table 2). As shown in
Figure 1, hospital mortality increased progressively with
Parsonnet scores > 20.
Twelve patients who died within six hours of admis-
sion to the ICU were excluded from further analysis,
leaving a total of 1,314 patients finally included in the
study.
Patients exposed to inotropes differed from those
unexposed in that they were older; had higher Parsonnet
scores, more comorbid illnesses and lower preoperative
left ventricular ejection fractions; were more likely to
have undergone valvular or combined procedures; and
had longer bypass times. However, at six hours after
ICU admission, aside from serum lactate, which was
higher in the group of patients exposed to inotropes,
postoperative physiological parameters were very similar.
The hospital mortality rate was seven times higher in
the group of patients exposed to inotropes compared to
those not exposed. Similarly, the rate of severe renal
failure was significantly higher in the patients exposed
to inotropes (Table 2).
We also examined the association of hospital mortality
and renal failure with the six-hour postadmission phy-
siological variables. As expected, the mortality was lower
in patients with higher measured cardiac indices, mixed
venous saturation, normal lactate values and higher cal-
culated oxygen delivery at six hours. However, the mor-
tality was significantly lower in patients unexposed to
inotropes even in the presence of six-hour measured
physiological variables lower than recommended thresh-
old values. The odds of dying in the hospital were four
to eight times higher in thei n o t r o p ee x p o s e dg r o u p
than in the unexposed group for similar levels of mea-
sured physiologic variables (Figure 2). A similar relation-
ship was found for renal dysfunction (Figure 3).
As a low preoperative left ventricular ejection fraction
may have increased the likelihood that a patient would be
treated with inotropes, the effect of inotropes on mortal-
ity in the 232 patients with preoperative left ventricular
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a
Variables and outcomes Total cohort
(N = 1,314)
Inotrope-unexposed (n = 783) Inotrope-exposed
(n = 531)
Postoperative inotrope and vasopressor use, n (%)
Norepinephrine 674 (51.3) 279 (35.6) 395 (74.4)
Vasopressin 73 (5.6) 5 (0.6) 68 (12.8)
Epinephrine 308 (23.29) 0 308 (58.0)
Dobutamine 75 (5.7) 0 75 (14.1)
Milrinone 332 (25.3) 0 332 (62.5)
Six-hour postoperative physiological variables
Mean arterial pressure, mmHg (± SD) 75.9 (10.0) 76.7 (10.0) 74.5 (9.7)
Mean oxygen delivery, mL/minute/m
2
(± SD)
353 (101) 363 (100) 341 (98)
Mean cardiac index, L/min (± SD) 2.9 (0.7) 2.9 (0.7) 2.8 (0.7)
Mixed venous oxygen saturation, n (%) 70.7 (9.0) 71.3 (8.2) 70.1 (9.3)
Mean serum lactate, μmol/L (± SD) 3.2 (2.7) 2.1 (1.6) 4.1 (3.0)
Outcomes
Died, n (%) 103 (7.8) 15 (1.9) 76 (14.3)
Renal dysfunction, n (%) 105 (8.3) 25(3.2) 87 (16.8)
Median ICU length of stay, days (IQR) 1.1(1.8) 1.0 (0.9,1.6) 2.1 (1.0,4.7)
Median hospital length of stay, days (IQR) 8 (6) 7.0 (5.0,9.0) 10.0 (6.0,18.0)
aIQR, interquartile range; SD, standard deviation.
Table 1 Baseline characteristics for total cohort and patient subgroups
a
Characteristics Total cohort (N = 1,326) Inotrope-unexposed (n = 783) Inotrope-exposed (n = 531)
Demographics
Mean age (± SD) 66.1 (11.0) 64.6 (10.7) 68.3 (11.0)
Age ≥ 80 years, n (%) 123 (9.3) 51 (6.5) 72 (13.6)
Females, n (%) 404 (30.5) 188 (24.0) 207 (39.0)
Mean Parsonnet score (± SD) 13.4 (10.6) 10.5 (8.3) 17.2 (11.7)
Medical history
Prior cardiac surgery, n (%) 78 (5.9) 26 (3.3) 48 (9.0)
Hypertension, n (%) 904 (68.2) 534 (68.2) 362 (68.2)
Diabetes, n (%) 417 (31.5) 220 (28.1) 193 (36.4)
Atrial fibrillation, n (%) 135 (10.2) 53 (6.8) 80 (15.1)
Preoperative CHF, n (%) 179 (13.5) 79 (10.1) 99 (18.6)
Preoperative renal dysfunction, n (%) 94 (7.1) 31 (4.0) 61 (11.5)
Preoperative dialysis, n (%) 21 (1.6) 9 (0.7) 12 (2.3)
Mean LVEF (± SD) 49.7 (11.8) 53.3 (11.8) 44.4 (15.8)
LVEF < 30%, n (%) 241 (18.2) 74 (9.5) 162 (30.5)
Procedure-related variables
CABG only, n (%) 912 (68.8) 601 (76.8) 303 (57.1)
Other procedure, n (%) 414 (31.2) 182 (23.2) 228 (42.9)
Perioperative IABP, n (%) 132 (10.0) 30 (3.8) 96 (18.1)
Received inotropes intraoperative, n (%) 666 (50.7) 219 (28.0) 447 (84.2)
Emergency operation, n (%) 132 (10.0) 58 (7.4) 74 (13.9)
Reoperation, n (%) 78 (5.9) 20 (2.6) 35 (6.6)
Mean bypass time, minutes (± SD) 101.2 (45.7) 86.8 (32.8) 120 (52)
Severe postoperative bleeding, n (%) 50 (3.8) 15 (1.1) 35 (6.6)
aCHF, congestive heart failure; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass graft; IABP, intraaortic balloon pump; SD, standard deviation.
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who received inotropes had significantly higher mortality
than patients who did not, with an odds ratio OR of 14.7
(95% confidence interval (95% CI) 2.0 to 11.1).
After adjusting for differences in Parsonnet score, left
ventricular ejection fraction, perioperative intraaortic
balloon pump use, bypass time, reoperation and cardiac
index, exposure to inotropes was associated with
increased hospital mortality (adjusted OR 2.3, 95% CI
1.2 to 4.5; P = 0.01) (Table 3). Receipt of inotropes was
also significantly associated with increased odds of renal
dysfunction (adjusted OR 2.7, 95% CI 1.6 to 4.7; P <
0.001) (Table 4). There were no differences in these
associations when treatment hospital, preoperative renal
dysfunction or aprotinin use was included in the regres-
sion analysis. As these variables did not confound the
association between the exposures and outcomes, they
were not included in the final regression model.
Using greedy one-to-five matching, 123 inotrope-
exposed patients were matched to 123 unexposed patients
using one-digit matching only. Only preoperative left ven-
tricular ejection fraction was statistically significantly dif-
ferent between the two groups, although equal numbers of
patients had left ventricular ejection fractions < 30%. Hos-
pital mortality, renal dysfunction, ICU and hospital length
of stay were significantly worse in the patients exposed to
inotropes (Table 5).
Discussion
In this observational study, postoperative inotrope expo-
sure was associated with increased hospital mortality
and renal dysfunction in cardiac surgery patients. Hospi-
tal mortality and renal dysfunction were consistently
lower in patients unexposed to inotropes, even when
their six-hour physiological variables were lower than
the targets recommended in the literature [3,10]. The
relationship between inotrope exposure and poor out-
comes remained significant after adjusting for differ-
ences in Parsonnet score, left ventricular ejection
fraction, perioperative intraaortic balloon pump use,
bypass time, reoperation and cardiac index. In addition,
an analysis using propensity score matching produced
similar results.
The demonstration of poorer outcomes in patients
exposed to inotropes is consistent with the results demon-
strated in several previous studies. An observational study
of patients who received dobutamine after cardiac surgery
demonstrated increased cardiac morbidity after the data
were adjusted for confounders [8]. Milrinone has also
been described as being associated with an increased risk
of postoperative atrial fibrillation in a cardiac surgery
population [12]. Further evidence that inotropes may be
harmful can be found in the heart failure literature. Ran-
domised, controlled trials of patients with decompensated
heart failure treated with phosphodiesterase inhibitors ver-
sus placebo revealed that those in the treatment group
experienced more episodes of hypotension and cardiac
arrhythmia and had higher mortality rates [13-15].
Furthermore, despite promising initial results, levosimen-
dan, a new class of inotrope, was not shown to be superior
to dobutamine in a randomised, controlled trial of patients
with acute heart failure and left ventricular ejection frac-
tions < 30% [16]. Researchers who conducted a systematic
review of controlled trials of b-adrenergic agents com-
pared to either placebo or an active agent in patients with
heart failure concluded that there is very little evidence
that treatment improves symptoms or patient outcomes
and may in fact be harmful [9]. Inotrope use was also asso-
ciated with increased mortality in a recent observational
study of heart failure with an effect size similar in magni-
tude to that found in our study [17].
Since the 1970s, a number of randomised trials have
been undertaken in medical and surgical patients to inves-
tigate whether targeting specific resuscitation goals, such
as cardiac output and oxygen delivery, would improve
patient outcomes [18]. Achieving the prespecified goals
often involved the use of inotropic medications to increase
cardiac output and oxygen delivery. Such therapy, referred
to as ‘goal-directed therapy’, has been associated with
improved outcomes, primarily in patients with sepsis and
in certain high-risk surgical patient populations [10,19].
However, these trials differed with regard to patient mix,
physiologic targets, therapies used and management of
control arms [20].
Four controlled studies have been published in which a
goal-directed therapy protocol was used in the cardiac
surgery setting [21-23]. The trials differed with regard to
targeted goals, therapeutic protocols and use of inotropic
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Figure 1 Hospital mortality by Parsonnet score in a cohort of
1,326 cardiac surgery patients. Error bars indicate 95% confidence
intervals (95% CIs).
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f l u i di n f u s i o n s ,d e m o n s t r a t e di m p r o v e dp h y s i o l o g i c a l
goals with minimal catecholamine use. The largest trial,
which targeted mixed venous oxygen saturation, demon-
strated shortened hospital stay and less morbidity, but
these outcomes were associated with increased catechola-
mine use. The last trial, which enrolled 30 patients in
total, demonstrated no significant difference in outcomes
but did require a more intense inotrope regimen to attain
the specified goals. Despite demonstrating improved clin-
ical outcomes, all four studies were underpowered to
detect any difference in mortality. Furthermore, two of
the four protocols required greater catecholamine doses
to achieve their goals.
Several mechanisms may explain the increased mortal-
ity observed in patients exposed to inotropes. The two
most common side effects of inotropic medications are
increased myocardial oxygen consumption and cardiac
arrhythmia. Both of these side effects may lead to poor
cardiac performance [7]. Alternatively, low cardiac out-
put may be due to mechanical obstruction, as in cardiac
tamponade, which may require surgical intervention.
The use of inotropes in these situations may transiently
improve the haemodynamic state but ultimately lead to
further harm, as appropriate diagnosis and treatment
may be either delayed or missed altogether. Further-
more, catecholamine use has been associated with
reduced metabolic efficiency by promoting fatty acid
oxidation over that of glucose. This may be a further
impediment to optimal cardiac performance. Catechola-
mine use has also been associated with bacterial growth,
increased bacterial virulence, biofilm formation, insulin
resistance and hyperglycaemia, all of which may contri-
bute to poor outcomes [25].
Figure 2 Hospital mortality stratified by (A) oxygen delivery, (B) cardiac index, (C) serum lactate and (D) mixed venous oxygen
saturation. Two groups of patients are represented (inotrope-exposed and inotrope-unexposed). The adjusted odds ratios for the association
between inotrope exposure and mortality were 8.5 (95% CI 4.8 to 15.0) after adjusting for oxygen delivery and 7.7 (95% CI 4.4 to 13.7) after
adjusting for cardiac index. The adjusted odds ratios for the association between inotropes exposure and mortality were 5.7 (95% CI 2.4 to 13.5)
after adjusting for serum lactate and 5.3 (95% CI 2.4 to 11.4) after adjusting for mixed venous oxygen saturation. Error bars indicate 95% CI. Data
from only one hospital were used for analyses of serum lactate and mixed venous oxygen saturation, resulting in wider 95% CIs.
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likely to be biased by a single centre’s practice pattern, as
the patients were recruited from two centres. Second, as
we routinely collected postoperative physiological data, we
were able to adjust for important haemodynamic variables.
Finally, because extensive preoperative, intraoperative and
postoperative data were collected, we were able to control
for many potential confounding factors.
The study’s main limitation is that it is an observa-
tional study, and thus the associations could be due to
residual confounding. Specifically, we may not have fully
adjusted the data for confounding by indication and
confounding due to severity of illness. To minimise con-
founding, we performed multiple different analyses,
including a propensity-matched analysis.
Conclusions
The results of our study demonstrate that inotrope
exposure was associated with increased hospital mortal-
ity and renal dysfunction in cardiac surgery patients.
The observational nature of the data and the potential
for confounding precludes any final conclusions about a
causal relationship. Nevertheless, the significant practice
variations reported in the literature, and the consistency
of our results with those reported in the cardiac surgery
and heart failure literature, demonstrate the need for
future research [4-6,26]. As inotropes may be associated
with increased morbidity and mortality, adequately pow-
ered, randomised, controlled trials are needed to clarify
the risks and benefits of inotrope use in cardiac surgery
patients.
Figure 3 Renal dysfunction stratified by (A) oxygen delivery, (B) cardiac index, (C) serum lactate and (D) mixed venous oxygen
saturation. Two groups of patients are represented (inotrope-exposed and inotrope-unexposed). The adjusted odds ratios for the association
between inotrope exposure and renal dysfunction were 6.0 (95% CI 3.8 to 9.5) after adjusting for oxygen delivery and 5.9 (95% CI 3.7 to 9.6) after
adjusting for cardiac index. The adjusted odds ratios for the association between inotrope exposure and mortality were 5.6 (95% CI 2.8 to 11.2)
after adjusting for serum lactate and 5.3 (95% CI 2.5 to 10.9) after adjusting for mixed venous oxygen saturation. Error bars indicate 95% CI. Data
from only one hospital were used for analyses of serum lactate and mixed venous oxygen saturation, resulting in wider 95% CIs.
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a
Variable Crude odds ratio Adjusted odds ratio (95% CI) P value
Inotrope status
Inotrope unexposed (ref) 1.0 1.0
Inotrope exposed 9.1 2.3 (1.2 to 4.5) 0.01
Parsonnet score
0 to 9 (ref) 1.0 1.0
10 to 14 2.4 1.8 (0.7 to 4.6) 0.24
15 to 19 3.1 1.8 (0.7 to 4.9) 0.23
20 to 29 8.3 4.6 (2.0 to 10.9) < 0.001
≥ 30 24.6 11.2 (4.6 to 27.5) < 0.001
Ejection fraction
LVEF ≥ 30% 1.0
LVEF < 30% 2.2 1.5 (0.9 to 2.7) 0.15
Intraaortic balloon pump use
No perioperative IABP use 1.0
Perioperative IABP use 8.2 3.3 (1.9 to 5.8) < 0.001
Bypass time
b 1.6 1.3 (1.1 to 1.4) < 0.001
Reoperative status
No reoperation 1.0
Reoperation 6.1 4.7 (2.3 to 9.3) < 0.001
Cardiac index at six hours, L/min
Cardiac index ≥ 2.2 (ref) 1.0 1.0
Cardiac index < 2.2 2.8 1.7 (0.93 to 1) 0.09
aLVEF, left ventricular ejection fraction; IABP, intraaortic balloon pump; ref, reference value; CI, confidence interval;
bmodelled linearly as an increase in bypass
time of 30 minutes.
Table 4 Multivariable analysis of association between inotrope exposure and renal dysfunction
a
Variable Crude odds ratio Adjusted odds ratio (95% CI) P value
Inotrope status
Inotrope unexposed (ref) 1.0 1.0
Inotrope exposed 7.5 2.7 (1.5 to 4.6) < 0.001
Parsonnet score
0 to 9 (ref) 1.0 1.0
10 to 14 1.5 1.2 (0.7 to 2.4) 0.59
15 to 19 2.1 1.4 (0.7 to 2.9) 0.35
20 to 29 3.6 2.3 (1.2 to 4.3) 0.01
≥ 30 6.5 2.8 (1.3 to 6.1) 0.007
Ejection fraction
LVEF ≥ 30% 1.0
LVEF < 30% 1.6 1.0 (0.6 to 1.7) 0.97
Intraaortic balloon pump use
No perioperative IABP use 1.0
Perioperative IABP use 5.4 2.7 (1.6 to 4.7) < 0.001
Bypass time
b 1.5 1.2 (1.1 to 1.4) < 0.001
Reoperative status
No reoperation 1.0
Reoperation 4.5 2.3 (1.2 to 4.5) 0.02
Renal dysfunction
Normal preoperative renal function 1.0
Preoperative renal dysfunction 3.7 1.7 (0.8 to 3.6) 0.14
Cardiac index at six hours, L/min
Cardiac index ≥ 2.2 (ref) 1.0 1.0
Cardiac index < 2.2 1.7 1.0 (0.6 to 1.9) 0.88
aLVEF, left ventricular ejection fraction; IABP, intraaortic balloon pump; ref, reference value; CI, confidence interval;
bmodelled linearly as an increase in bypass
time of 30 minutes.
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￿ Postoperative inotrope exposure was independently
associated with hospital mortality and renal
dysfunction.
￿ The increased hospital mortality and renal dys-
function in patients exposed to inotropes are
observed even when recommended six-hour physio-
logical variables are achieved.
￿ Patients unexposed to inotropes with six-hour phy-
siological variables below recommended targets had
lower mortality than patients exposed to inotropes
who achieved these targets.
Abbreviations
CABG: coronary artery bypass and graft; CI: confidence interval; SD: standard
deviation.
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